ZV 203

Drug Profile

ZV 203

Alternative Names: ZV203

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Concortis Biotherapeutics
  • Class Antibodies; Drug conjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 25 Nov 2016 Concortis Biotherapeutics plans a clinical trial for Gastric cancer and Breast cancer (Concortis Biotherapeutics pipeline, November 2016)
  • 25 Nov 2016 Preclinical trials in Cancer in USA (Parenteral) (Concortis Biotherapeutics pipeline, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top